Vertex Pharmaceuticals Inc
Stock Chart, Company Information, and Scan Results
$463.31(as of Dec 3, 3:59 PM EST)
Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.
Vertex Pharmaceuticals Inc Company Information, Fundamentals, and Technical Indicators
Stock Price$463.31
Ticker SymbolVRTX
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees6,100
CountyUSA
Market Cap$111,055.6M
EBIDTA4,711.8M
10-Day Moving Average431.16
P/E Ratio32.46
20-Day Moving Average429.01
Forward P/E Ratio22.32
50-Day Moving Average418.13
Earnings per Share14.47
200-Day Moving Average443.02
Profit Margin35.20%
RSI71.14
Shares Outstanding253.7M
ATR11.51
52-Week High519.68
Volume2,542,279
52-Week Low362.50
Book Value17,318.8M
P/B Ratio6.89
Upper Keltner454.91
P/S Ratio10.18
Lower Keltner403.10
Debt-to-Equity Ratio454.91
Next Earnings Date02/04/2026
Cash Surplus464.3M
Next Ex-Dividend DateUnknown
Vertex is a biotech leader that focuses on cutting-edge research and the development of transformative medicines for people with life-threatening diseases. The company has built a reputation for developing groundbreaking treatments that target the underlying cause of genetic diseases rather than just treating symptoms. Their flagship product, Trikafta, has shown remarkable results in treating cystic fibrosis.
Vertex Pharmaceuticals Inc In Our Stock Scanner
As of Dec 04, 2025
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
Scan Name: Unusual VolumeScan Type: Stock Indicator Scans
As of ---
Scan Name: Momentum StocksScan Type: Stock Indicator Scans
As of ---
Scan Name: Increasing Book ValueScan Type: Stock Fundamentals
As of ---
Scan Name: Increasing Profit MarginScan Type: Stock Fundamentals
As of ---
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
Join Our Free Email List
Get emails from us about ways to potentially make money in the stock market.